Month: December 2020

Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio Companies will develop a transition plan with the goal of returning full commercialization responsibilities to AstraZeneca in 2021Companies will ensure availability of Lumoxiti to patients during transition periodConference call to be held today at 2 pm CET / 8 am ETMARSEILLE, France, Dec. 11, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return the US and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca1. Innate licensed the US and EU rights to AstraZeneca’s FDA-approved Lumoxiti for certain patients with relapsed or refractory hairy cell leukemia in...

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderlyPhase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 yearsInsufficient response in older adults demonstrates the need to refine the concentration of antigen in order to provide high-level immune response across all age groupsCompanies plan a Phase 2b study with an improved antigen formulationWith support from BARDA as part of Operation Warp Speed, study to start in February 2021, including a proposed comparison with an authorized COVID-19 vaccineProduct availability now expected in Q4 2021 pending successful completion of the development plan  PARIS and LONDON – December 11, 2020 – Sanofi and GSK announce a delay in their...

Sanofi et GSK annoncent un retard dans leur programme de vaccin adjuvanté à protéine recombinante contre la Covid-19 afin d’améliorer la réponse immunitaire chez les personnes âgéesChez des adultes âgés de 18 à 49 ans, les résultats intermédiaires de phase I/II ont montré une réponse immunitaire comparable à celle des patients qui se sont rétablis d’une infection Covid-19.La réponse insuffisante observée chez les adultes plus âgés souligne la nécessité d’affiner la concentration d’antigènes de manière à obtenir une réponse immunitaire élevée dans toutes les tranches d’âge.Les entreprises prévoient une étude de phase IIb avec une formulation d’antigène amélioréeAvec le soutien de la BARDA et dans le cadre de l‘Operation Warp Speed, l’étude de phase IIb démarrera en février 2021, comprenant une proposition de comparaison avec...

Marseille, Dec. 11, 2020 (GLOBE NEWSWIRE) —Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio  Companies will develop a transition plan with the goal of returning full commercialization responsibilities to AstraZeneca in 2021 Companies will ensure availability of Lumoxiti to patients during transition period Conference call to be held today at 2 pm CET / 8 am ETInnate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will return the US and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca1.  Innate licensed the US and EU rights to AstraZeneca’s FDA-approved Lumoxiti for certain patients with relapsed or refractory hairy cell leukemia in October...

Marseille, 11 déc. 2020 (GLOBE NEWSWIRE) —Innate ne poursuivra pas les activités de commercialisation de Lumoxiti aux Etats-Unis et en Europe ; la Société recentre ses investissements sur son portefeuille de R&DLes sociétés mettront en place un plan de transition avec l’objectif de retourner l’ensemble des responsabilitiés commerciales à AstraZeneca en 2021Les sociétés assureront la disponibilité de Lumoxiti pour les patients pendant la période de transitionUne conférence téléphonique à destination des analystes se tiendra aujourd’hui à 14h00 CETInnate Pharma SA (Euronext Paris : IPH – ISIN : FR0010331421 ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd’hui qu’elle retournera les droits commerciaux de Lumoxiti (moxetumomab pasudotox-tdfk) aux Etats-Unis et en Europe à AstraZeneca1. Innate avait pris en licence...

The Elecsys® SARS-CoV-2 Antigen test is an automated laboratory assay intended as an aid in the diagnosis of active SARS-CoV-2 infectionRoche will be able to ramp up to a double-digit million number of tests per month, by early 2021The test is the latest addition to Roches comprehensive COVID-19 portfolio and can help in the management of patients for optimal care deliveryBasel, 11 December 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has launched a high-throughput SARS-CoV-2 antigen test as an aid in the diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections, in markets accepting the CE Mark. Roche has also filed for Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration.The Elecsys® SARS-CoV-2 Antigen test is a highly accurate laboratory immunoassay for the...

Coop Panga 2020. aasta novembri majandustulemused:Panga klientide arv kasvas novembris 2100 võrra ja ulatus kuu lõpuks 84 100-ni. Aastaga on kliendibaas kasvanud 36%.Panga klientide hoiuste maht kahanes novembris 3 miljoni euro võrra ulatudes novembri lõpu seisuga 746 miljoni euroni. Kodumaiste äri- ja eraklientide hoiused kasvasid kokku 11 miljonit eurot, peamiselt rahvusvahelistelt hoiuseplatvormidelt kaasatud hoiuste maht vähenes 14 miljonit eurot. Aastaga on panga hoiuste maht kasvanud 47%.Panga neto laenuportfell kasvas novembris 18,5 miljoni euro võrra ja jõudis kuu lõpu seisuga 645 miljoni euroni. Aastaga on panga laenuportfell kasvanud 44%.Laenude allahindluse kulu oli novembris 0,5 miljonit eurot.Aastaga on panga netotulud kasvanud 32% ja tegevuskulud 16%. Pank teenis novembris 660 tuhat eurot puhaskasumit. Käesoleva aasta 11...

Baltika will continue with implementation of business model based on renewed strategy, focusing going forward only on developing and marketing women clothing brand Ivo Nikkolo.Focusing on one brand allows to reduce the cost base and allows easier entrance to key markets to expand sale possibilities. Company´s target is to develop from Ivo Nikkolo international brand, starting from Baltic countries and moving onward to other Central and Eastern-European countries. The collection of Ivo Nikkolo will be contemporary and the target is to offer clients quality products with reasonale prices partly from spring-summer 2021 and fully from autumn-winter. In the same time offer strong client experience in stores as well as through e-stores and platforms.Ivo Nikkolo head designer is Margot Vaaderpass, who has wide and international experience,...

Baltika Grupp jätkab uuenenud strateegial põhineva ärimudeli elluviimist, keskendudes edaspidi vaid naisterõivaste brändi Ivo Nikkolo arendamisele ja turustamisele.Ühele brändile keskendumine võimaldab vähendada kulubaasi ja võimaldada lihtsamini siseneda võtmeturgudele müügivõimaluste laiendamiseks. Ettevõtte eesmärk on arendada Ivo Nikkolost rahvusvaheline bränd, alustades Baltikumist ja liikudes edasi teistesse Kesk- ja Ida-Euroopa riikidesse. Osaliselt alates 2021. aasta kevadsuvest ja täismahus sügistalvest saab Ivo Nikkolo kollektsioon olema kaasaegne ning eesmärk on pakkuda klientidele kvaliteetseid tooteid mõistlikul hinnatasemel. Samuti pakkuda ühtlaselt tugevat kliendikogemust nii kauplustes kui ka veebipoodides ja -platvormidel.Ivo Nikkolo peadisaineriks on laialdase ning rahvusvahelise kogemusega Margot Vaaderpass, kes on...